Linking Placental Ischemia and Hypertension
in Preeclampsia
Role of Endothelin 1

Eric M. George, Joey P. Granger

One of the most pervasive disorders of pregnancy is preeclampsia, which is defined as new-onset hypertension presenting after the 20th week of gestation and is accompanied by increasing levels of proteinuria and often edema.1 The overall prevalence of preeclampsia is ≈8% with higher incidence in specific ethnic subpopulations, notably blacks.2,3 The disorder is predominantly a complication of primiparous women, who have a 3-fold higher incidence rate than multiparous women. There are a number of known factors that convey elevated risk of developing preeclampsia, notably elevated body mass index, and a previous incidence of preeclampsia, because women who experienced preeclampsia in previous pregnancies are 7 times more likely to exhibit preeclamptic symptoms in subsequent pregnancies than those with no history of preeclampsia.4 It has also been shown that high body mass index can double the risk of preeclampsia, and the scale of obesity correlates directly with the increase risk of developing the disorder.5 Although the link between these risk factors seem logical, there are also a number of other risk factors (maternal age, induced abortions, interpregnancy interval, and socioeconomic factors) for which the links to preeclampsia are not as clear.6 More research is warranted into the mechanistic effect of these factors in the etiology of preeclampsia.

There are currently no definitive treatment options for the resolution of preeclampsia. Available interventions are confined to magnesium sulfate for the prophylaxis of seizures and the administration of one of various antihypertensive agents, although normalization of blood pressure is not normally possible, and the disease continues to progress.1 Indeed, the only effective resolution of preeclampsia is delivery of the placenta, because delivery of the fetus alone is not sufficient.7,8 It is this fact that suggested the pathological origins of the development of preeclampsia. Although the underlying molecular mechanisms that lie at the root of preeclampsia are not clear, it is believed that a major causative agent is placental insufficiency resulting from inadequate remodeling of the maternal vasculature.9 During normal pregnancy, fetally derived cytotrophoblasts invade the maternal spiral arteries of the uterus, replace the maternal endothelium, and undergo differentiation into an endothelial-like phenotype. This causes a conversion of the high-resistance, small-diameter vessels into high-capacitance, low-resistance vessels and ensures adequate delivery of maternal blood to the developing uteroplacental unit.10 In the preeclamptic patient, unknown errors in this carefully orchestrated scheme lead to inadequate delivery of blood to the developing uteroplacental unit and create hypoxia and chronic ischemia within the placenta.11 In response, the placenta produces pathogenic factors that enter the maternal bloodstream and are responsible for the clinical manifestations of the disorder. Among the factors known to be released, antiangiogenic and autoimmune/inflammatory factors have received a great deal of attention. Interestingly, recent evidence suggests that these agents have a final common pathway, activation of the endothelin 1 (ET-1) system.

There are several lines of evidence that suggest a pathogenic role for ET-1 in the preeclamptic patient. A number of studies looking at circulating levels of ET-1 in preeclamptic women have generally demonstrated significantly higher levels of circulating ET-1 in the plasma of preeclamptic patients when compared with healthy controls, with some suggestion that a genetic polymorphism could play a role in the variation of ET-1 levels.12–16 However, circulating levels of ET-1 are not necessarily good indicators of ET-1 production in the tissues because of the fact that ET-1 secretion is directionally, with a larger proportion of the peptide being released on the basolateral side of the endothelium, and tissue levels may not be accurately reflected in the levels of ET-1 in the circulation. Studies indicating elevations in ET-1 in preeclamptic placental cells are perhaps more telling, although this is not a universal finding.17,18 Finally, one report has indicated an increase in endothelin-converting enzyme in the circulation of preeclamptic patients compared with normal pregnant controls, suggesting a potential mechanism for enhanced local production of ET-1.19 These data support earlier studies demonstrating increased endothelin-converting
enzyme production by endothelial cells exposed to pre eclamptic serum. There are also indications that matrix metalloproteinase 2, which can also cleave big endothelin into ET-1, is significantly elevated in preeclamptic women. These findings suggest at least a correlation between ET-1 and preeclampsia in humans and warrant further study.

Because studies on pregnant women are, at best, complicated, a number of experimental animal models have been used to examine the etiology and development of preeclampsia. One that we and others have used with great success is the reduced uterine perfusion pressure (RUPP) model, which mechanically restricts blood flow to the placenta, leading to hypoxia and ischemia. This model has been used in species ranging from rats to nonhuman primates and mimics a number of the pathological features of human preeclampsia, including hypertension, angiogenic imbalance, renal injury, proteinuria, and endothelial dysfunction. In studies where human endothelial cells were exposed to serum from RUPP rats in vitro, it was shown that RUPP sera significantly induced production of ET-1 from the endothelial cells when compared with those exposed to serum from normal pregnant animals, suggesting that circulating factors produced by placental ischemia are responsible for increased vascular ET-1 production. Initial in vivo studies suggested that both the renal cortex and medulla of RUPP rats express significantly higher levels of the ET-1 precursor, preproendothelin, at the mRNA level when compared with normal pregnant controls (Figure 1B and 1C). Crucially, when an endothelin A (ETₐ) receptor antagonist was administered to the RUPP rats, the associated hypertension was abolished (Figure 1A), and there was a trend for increased renal function. These studies suggest that placental ischemia induces factors that activate the production of ET-1 in the vasculature, which acts through ETₐ receptors to mediate the hypertension seen in this model. Whether similar ETₐ antagonism could prove effective in preeclamptic women remains to be seen.

**Soluble Fms-Like Tyrosine Kinase 1**

One of the most intensely studied pathways in the manifestation of preeclampsia is the vascular endothelial growth factor (VEGF) signaling pathway. VEGF, other than its role in angiogenesis, has an important role in the maintenance of proper endothelial cell function and health. This signaling pathway came to prominence with the discovery of elevated circulating and placentical levels of the soluble form of the VEGF receptor, Flt-1, denominated soluble Fms-like tyrosine kinase 1 (sFlt-1). sFlt-1 acts as a direct inhibitor of VEGF by binding to the protein and preventing it from being available for its normal function. Subsequent studies looking at the regulation of sFlt-1 in cell culture and placental tissue in vitro have demonstrated that sFlt-1 is released from placental villi and trophoblast cells in response to reduced oxygen tensions similar to that seen in the ischemic placenta. A promising recent pilot study demonstrated that sFlt-1 could be removed from the maternal circulation by apheresis safely and that this therapy reduced both blood pressure and proteinuria, with a trend toward increased gestational duration.

A number of groups have also reported that artificial elevation of sFlt-1 in animal models, either by direct infusion or by viral overexpression, leads to hypertension, renal injury, and proteinuria, all symptomatic of preeclampsia. These results are supported by clinical data showing that patients receiving the anti-VEGF antibody therapy Bevacizumab, which functions in much the same way as sFlt-1, exhibit marked proteinuria and hypertension. Kappers et al also reported that Sunitinib, a tyrosine kinase inhibitor which targets the VEGF receptor, induces a reversible rise in BP in patients and in rats associated with activation of the ET-1 system and generalized microvascular dysfunction. Finally, the same group recently reported that VEGF inhibition with Sunitinib in pigs results in endothelin-mediated hypertension in pigs. This suggests that another potential mechanism whereby VEGF blockade could increase BP is by enhancing ET-1 synthesis.

Several reports have been made into the role of the ET-1 system in models of sFlt-1 overexpression in pregnancy. In support of ET-1 as a mediator of sFlt-1–induced hypertension, our group has reported recently that continuous infusion of sFlt-1 in pregnant rats directly increased the level of ET-1 in the renal cortex and resulted in an increase in the mean arterial pressure of ~20 mmHg (Figure 2). Tellingly, with coadministration of an ETₐ receptor antagonist, the hypertension associated with this model was completely abolished, strongly supporting ET-1 as an important mediator of sFlt-1–induced hypertension.

**Autoimmune Factors**

One of the earliest and most persistent theories about the origins of preeclampsia view it as a disorder of immunity. In
fact, there is a growing realization that autoimmunity plays a pivotal role in the symptomatic phase of the disorder and perhaps the early etiology of the disease as well.\textsuperscript{45–47} The autoimmune components of preeclampsia can be compartmentalized into 2 headings, the production of autoantibodies and the innate immune response. In the first category, much attention has been focused on the production of argonotic angiotensin II type 1 receptor autoantibodies (AT 1-AA), which have been found in the circulation of women with preeclampsia and verified in several experimental models. Even more clearly characterized is the innate inflammatory response mediated by inflammatory cytokines. The importance of these 2 components has begun to be elucidated, and several experimental approaches have been used to understand their role in the development of preeclampsia.

One well-characterized component of the innate immune response to preeclampsia is the production of tumor necrosis factor-α (TNF-α), which is elevated in both preeclamptic women and rodents undergoing chronic placental ischemia.\textsuperscript{48–50} Previous studies in vitro demonstrated that production of ET-1 by endothelial cells could be driven by exposure to TNF-α.\textsuperscript{51} Studies from our group have demonstrated that administration of the soluble TNF-α receptor Etanercept is capable of attenuating the hypertension associated with placental ischemia in pregnant rats. This treatment is associated with reduced expression of the preproendothelin in the renal cortex and medulla, as well as the placenta itself.\textsuperscript{50} It has also been shown that infusion of TNF-α directly induced hypertension in pregnant rats, producing an \~20-mmHg increase in mean arterial pressure in late gestation. This is associated with a significant increase in the expression of preproendothelin in the maternal vasculature, placenta, and kidney. As in the RUPP model, coadministration of an ET\textsubscript{A} receptor antagonist in these animals completely abolished the associated hypertension (Figure 3).\textsuperscript{52} Together, these data suggest that TNF-α is an important component of the hypertensive response to placental ischemia and that ET-1, acting through the ET\textsubscript{A} receptor, is a crucial mediator of TNF-α–induced hypertension.

A relatively recent addition to the immune component of preeclampsia is the agonistic AT\textsubscript{1}-AAs. These antibodies were originally isolated just over a decade ago in preeclamptic women and have since been found in the circulation of rats undergoing placental ischemia.\textsuperscript{53,54} Interestingly, these antibodies appear to be induced by the production of TNF-α, because infusion of TNF-α to pregnant rats also results in production of the antibody at levels comparable to those seen in pregnant women and the RUPP rat.\textsuperscript{52} It has also been demonstrated that infusion of the AT\textsubscript{1}-AAs directly into pregnant rats results in moderate hypertension that is associated with increased preproendothelin expression in both the renal cortex and placenta. Again, administration of an ET\textsubscript{A} receptor antagonist abrogated the hypertensive response to the AT\textsubscript{1}-AA, suggesting its importance in the manifestation of AT\textsubscript{1}-AA–induced hypertension (Figure 4).\textsuperscript{53} However, the pathogenic importance of these antibodies remains to be fully elucidated, because their presence has been noted postpartum in a subset of preeclamptic patients with no discernible phenotype.\textsuperscript{56,57} It is likely, then, that these antibodies act

---

**Figure 2.** Soluble Fms-like tyrosine kinase 1 (sFlt-1) induces hypertension through endothelin 1 (ET-1) induction. Infusion of sFlt-1 significantly increases mean arterial pressure (MAP) in pregnant rats. This hypertensive response is completely blunted with administration of an endothelin A (ET\textsubscript{A})–selective antagonist (A). Production of preproendothelin mRNA is significantly increased in the renal cortex by sFlt-1 infusion (B). *P<0.05 vs controls; #P<0.05 vs sFlt-1–infused rats. Adapted from Murphy et al.\textsuperscript{36}

**Figure 3.** Tumor necrosis factor (TNF)-α induces hypertension through endothelin 1 (ET-1) induction. Infusion of TNF-α significantly increases mean arterial pressure (MAP) in pregnant rats. This hypertensive response is completely blunted with administration of an endothelin A (ET\textsubscript{A})–selective antagonist. *P<0.05 vs controls, #P<0.05 vs TNF-α–infused rats. Adapted from LaMarca et al.\textsuperscript{52}

**Figure 4.** Angiotensin II type 1 receptor autoantibody (AT\textsubscript{1}-AA) induces hypertension through endothelin 1 (ET-1) induction. Infusion of AT\textsubscript{1}-AA significantly increases mean arterial pressure (MAP) in pregnant rats, an effect that is blocked by an endothelin A (ET\textsubscript{A})–selective antagonist. *P<0.05 vs controls, #P<0.05 vs AT\textsubscript{1}-AA–infused rats. Reprinted from LaMarca et al.\textsuperscript{52}
more as modulators of the hypertensive phenotype begun by other pathogenic factors rather than as first-cause agents directly, possibly by enhancing the response of the ET-1 system. Further studies are needed to determine how these antibodies interact with the other pathogenic agents in preeclampsia to produce the clinical phenotype.

**Perspectives**

Given the myriad of experimental models of preeclampsia (placental ischemia, sFlt-1 infusion, TNF-α infusion, and AT₁-AA infusion), which have proven susceptible to ETA antagonism, could the ET-1 system be a therapeutic approach in managing the hypertension associated with preeclampsia? Excitement at this approach has been tempered by work showing that genetic knockout of the ETA receptor leads to birth defects and eventual embryonic lethality in mice. As a result, administration of endothelin receptor antagonists is contraindicated in pregnancy. However, studies that have examined pharmacological antagonism of the ETA receptor during pregnancy in rats have identified specific windows of development in early and midgestation in which the agents caused phenotypes similar to that seen in the knockout. Administration of the ETA antagonist only during late gestation was not performed, and it is entirely possible that ETA receptor antagonists might prove safe and efficacious in later pregnancy, when the symptoms of preeclampsia are most severe. We have also demonstrated recently that induction of heme oxygenase 1 in both placental ischemia and sFlt-1-induced hypertension significantly blunts blood pressure, in part by reducing vascular production of preproendothelin 1, suggesting another mechanism through which the ET-1 system could be targeted for the management of preeclampsia (Figure 5). Alternatively, development of ETA receptor antagonists that do not cross the placental barrier would circumvent these problems altogether. Further work to determine the transmission of existing agents, as well as the development of new antagonists, could provide a truly effective therapy for the management of hypertension in the preeclamptic patient.

**Sources of Funding**

This work was supported by National Institutes of Health grants HL51971, HL108618–01, and T32HL105324–01 and a postdoctoral fellowship from the American Heart Association (11POST7840039).

**Disclosures**

None.

**References**

George and Granger  Endothelin 1 in Preeclampsia  511


Linking Placental Ischemia and Hypertension in Preeclampsia: Role of Endothelin 1
Eric M. George and Joey P. Granger

Hypertension. 2012;60:507-511; originally published online May 7, 2012;
doi: 10.1161/HYPERTENSIONAHA.112.194845

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/60/2/507

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/